Navigation Links
Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference

LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology, Inc. (OTCBB:CGRB) today announced that positive Phase I and Phase II data on the Company's prostate cancer drug candidate CB7630 (abiraterone acetate) were presented at the European Society for Medical Oncology (ESMO) Conference, which is currently taking place in Lugano, Switzerland. The data were presented in two oral and poster presentations on Sunday, July 8, as part of the session for genitourinary (prostate) cancer that took place. The poster presentations are further detailed below:

Inhibition of androgen synthesis results in high response rate in castration resistant prostate cancer

The Phase I/II trial of CB7630 was conducted at The Institute of Cancer Research and at The Royal Marsden NHS Foundation Trust in the United Kingdom. In the trial, CB7630 was administered orally, once daily, to chemotherapy-naive patients with castration resistant prostate cancer (CRPC), who had progressive disease despite treatment with LHRH analogues and multiple other hormonal therapies. To date, a total of 47 patients have been treated in the Phase I/II trial, including 15 patients treated in the Phase I portion of the trial and 32 patients treated in the Phase II portion of the trial. Of the 38 patients who were evaluable, all of the patients had radiological evidence of metastatic disease. Moreover, all of the patients had previously failed treatment with LHRH analogs and antiandrogens, while 20 patients (53%) had failed treatment with diethylstilboestrol and 19 patients (50%) had failed treatment with steroids.

In her poster and oral presentation, Dr. Alison Reid from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in the United Kingdom reported that CB7630 was well tolerated at doses as high as 2000 mg/day with minimal toxicity. Moreover, no dose limiting toxicity has been observed in the trial to date.

'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:7/1/2015)... 1, 2015 Qiming Venture Partners, today announces ... Partner effective immediately. William has been with ... participated in many Qiming healthcare deals, and assisted many ... market. Qiming, s success in healthcare is not a ... himself with his outstanding advocacy and service mentality on ...
(Date:7/1/2015)... Research and Markets( ... "Future Horizons and Growth Strategies in the ... Country Forecasts" report to their offering. ... European Blood Banking Market 2015 is a new ... suppliers and potential market entrants identify and evaluate ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
Breaking Medicine Technology:Qiming Announces the Promotion of William Hu to Managing Partner 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4
... Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its ... will be issued on Friday, November 5th at 6:30 ... 8:30 a.m. Friday, November 5th - 8:30 a.m. E.D.T.If ... callers use:502-719-4466Password - DUSAA replay of the call will ...
... BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial -- CARMIEL, Israel, Nov. 2, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 2Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 3Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 4Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 5Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 6Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 7Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 8Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 9Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 10
(Date:7/2/2015)... ... July 02, 2015 , ... Evolved Ayurvedic Discoveries , ... an intention to partner with companies that share a similar mission of providing ... water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic herbs, are now available for ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Today, East Liverpool ... the Surgical Center at East Liverpool City Hospital (ELCH). Pam is currently the Chief ... of the director of surgery. Pam holds a master’s degree in health care administration ...
(Date:7/2/2015)... ... ... As part of the celebration of its 70th anniversary, the Thantakit International ... all around the world for their continuous patronage of the world-class services of their ... (indeed, Thantakit is one of the foremost places for dental tourism in Thailand) or ...
(Date:7/2/2015)... ... , ... Maddock Douglas is an internationally recognized firm that ... manage the increasing demand for innovation as a primary growth strategy, Maddock Douglas ... , Benkendorf is a seasoned management executive with more than 25 years of ...
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. ... Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and ... therapeutics against middle-ear infections. , The grant from the National Institute on Deafness ...
Breaking Medicine News(10 mins):Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3Health News:Thailand's Longest Established International Dental Center Celebrates Its 70th Anniversary with Promos Galore 2Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2
... 15, 2007 The U.S. Pharmacopeia (USP) is ... dietary supplements for public notice and comment. ... Isoflavones monographs appeared in Pharmacopeial Forum (PF) 33(6), ... Turmeric, Powdered Turmeric, Powdered Turmeric Extract, Curcuminoids, Curcuminoids ...
... Nov. 15 Medical Services,International Inc. (Pink Sheets: MSITF) ... excellent independent test results obtained by regulatory,agencies related to ... the dual,VScan test kit that detects HIV and TB ... to be closely associated. It is very difficult to,get ...
... Launches Highly Accessible and ... Affordable Program ... YORK, Nov. 15 Chefs Diet(R), the leading meal,delivery service provider based ... My Solution -- a nationwide program that provides,chef-prepared, gourmet frozen meals for ...
... for Driver Safety Highlighted, WASHINGTON, Nov. 15 ... will hit the roads to spend time,with family and ... of the,11 million Americans with uncorrected vision problems. Depending ... could have,been eighteen years ago and some may never ...
... a study of more than 6,000 Los Angeles-area children ... Keck School of Medicine of the University of Southern California ... wall-eyed) and amblyopia (often referred to as lazy eye) were ... The study is currently available in the online edition of ...
... of men co-infected with herpes simplex virus type 2 (HSV-2) ... the levels of HIV in the blood and rectal secretions, ... This study is published in the November 15 issue ... , Most HIV-infected persons are also infected with HSV-2, ...
Cached Medicine News:Health News:USP announces 11 new proposed monographs for dietary supplements 2Health News:Medical Services Gets Significant Interest in Its Dual VScan Test Kit 2Health News:CHEFS DIET(R) Introduces My Solution 2Health News:Report Shows Millions May Be Driving with Uncorrected Visual Impairments 2Health News:Report Shows Millions May Be Driving with Uncorrected Visual Impairments 3Health News:USC study -- largest of its kind -- finds older children more likely to develop vision disorders 2Health News:Study shows suppressing herpes virus may reduce infectiousness of HIV 2
... of Alcon Acrylic, Chiron/Iolab LI-41 and Pharmacia & ... taller and thinner, maximizing the surface area around ... during loading and insertion, and makes it easy ... lens optic. The special direct-acting jaws release the ...
... 599 is the first full-featured combination automatic ... response on refraction results with visual acuities. ... at either 90 or 180 to accommodate ... HARK to the Humphrey Lens Analyzers for ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
Prednisolone Acetate ophthalmic suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension....
Medicine Products: